메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 26, Issue 35, 2008, Pages 5829-
Cost effectiveness of sunitinib
Author keywords

[No Author keywords available]
Indexed keywords

INTERFERON; SUNITINIB;
EID: 57449120462     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8101     Document Type: Letter
Times cited : (3)
References (6)
  • 1
    • 0032539168 scopus 로고    scopus 로고
    • Cost-effectiveness analyses of statistically ineffective treatments
    • Trippoli S, Messori A: Cost-effectiveness analyses of statistically ineffective treatments. JAMA 280:1992-1993, 1998
    • (1998) JAMA , vol.280 , pp. 1992-1993
    • Trippoli, S.1    Messori, A.2
  • 2
    • 0034666033 scopus 로고    scopus 로고
    • Survival gain in cost-effectiveness studies
    • Trippoli S, Vaiani M, Messori A, et al: Survival gain in cost-effectiveness studies. J Clin Oncol 18:3318, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 3318
    • Trippoli, S.1    Vaiani, M.2    Messori, A.3
  • 3
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alpha in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 4
    • 50549086998 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    • Remák R, Charbonneau C, Négrier S, et al: Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 26:3995-4000, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3995-4000
    • Remák, R.1    Charbonneau, C.2    Négrier, S.3
  • 5
    • 33645505995 scopus 로고    scopus 로고
    • Bias in published cost-effectiveness studies: Systematic review
    • Bell CM, Urbach DR, Ray JG, et al: Bias in published cost-effectiveness studies: Systematic review. BMJ 332:699-703, 2006
    • (2006) BMJ , vol.332 , pp. 699-703
    • Bell, C.M.1    Urbach, D.R.2    Ray, J.G.3
  • 6
    • 85007729412 scopus 로고    scopus 로고
    • Industry-sponsored studies twice as likely to have positive conclusions about costs
    • Dobson R: Industry-sponsored studies twice as likely to have positive conclusions about costs. BMJ 327:1006, 2003
    • (2003) BMJ , vol.327 , pp. 1006
    • Dobson, R.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.